### CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the period from 1 January 2016 to 30 June 2016

### CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the period from 1 January 2016 to 30 June 2016

### CONTENTS

	Page
Independent Auditors' report on review of condensed consolidated interim financial statements	1
Condensed consolidated interim statement of comprehensive income	2
Condensed consolidated interim statement of financial position	3
Condensed consolidated interim statement of changes in equity	4 & 5
Condensed consolidated interim statement of cash flows	6 & 7
Notes to the condensed consolidated interim financial statements	8 - 18



KPMG Limited
Chartered Accountants
11, June 16th 1943 Street, 3022 Limassol, Cyprus
P.O.Box 50161, 3601 Limassol, Cyprus
T: +357 25 869000, F: +357 25 363842

### INDEPENDENT AUDITORS' REPORT ON REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

TO THE MEMBERS OF

MD MEDICAL GROUP INVESTMENTS PLC

### Introduction

We have reviewed the accompanying condensed consolidated interim statement of financial position of MD Medical Group Investments Plc and its subsidiaries ("the Group") as at 30 June 2016, the condensed consolidated interim statements of comprehensive income, changes in equity and cash flows for the six- month period then ended, and notes to the interim financial statements ("the condensed consolidated interim financial statements"). Management is responsible for the preparation and presentation of this condensed consolidated interim financial statements in accordance with IAS34 "Interim Financial Reporting". Our responsibility is to express a conclusion on this condensed consolidated interim financial statements based on our review.

### Scope of Review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." A review of interim financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

### Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements as at 30 June 2016 is not prepared, in all material respects, in accordance with IAS 34 "Interim Financial Reporting".

Zak s E. Hadjizacharias, CA

Certified Public Accountant and Registered Auditor

for and on behalf of

KPMG Limited Certified Public Accountants and Registered Auditors

11, June 16th 1943 Street 3022 Limassol Cyprus

2 September 2016

Board Members

N.G. Syrimis, A.K. Christofides, P.G. Loizou, A.M. Gregoriades, A.A. Demetriou, D.S. Vakis, A.A. Apostolou, S.A. Loizides, M.A. Loizides, S.G. Sofocleous, M.M. Antoniades, C.V. Vasiliou, P.E. Antoniades, M.J. Halios, M.P. Michael, P.A. Peleties, G.V. Markides, M.A. Papacostat, K.A. Papanicolatou, A.I. Shiammoutis, G.N. Tziortzis, H.S. Charalambous, C.P. Anaylotos, I.P. Ghalanos, M.G. Gregoriades, H.A. Kakoullis, G.P. Savva, C.A. Kalias, C.N. Kallis, M.H. Zavrou, P.S. Elia, M.G. Lazarou, Z.E. Hadjizacharias, P.S. Theophanous, M.A. Karantoni, C.A. Markides, G.V. Andreou, J.C. Nicolaou, G.S. Prodromou, A.S. Sofocleous, G.N. Syrimis, T.J. Yiasemides

Paphos P.O. Box 60288, 8101 T. +357 26.943050

Nicosia P.O. Box 21121, 1502 T: +357 22 209000 F: +357 22 678200

F: +357 23 820084 Polis Chrysochou P O: Box 66014, 833

KPMG Limited, a private company limited by shares, registered in Cyprus under registration number HE 132822 with its redistered office at 14. Esperidon Street 1087. Nicosia. Compus.

### CONDENSED CONSOLIDATED INTERIM STATEMENT OF COMPREHENSIVE INCOME

### For the period from 1 January to 30 June

	Note	2016 RUB'000	2015 RUB'000
Revenue Cost of sales	4 5	5,814,297 (3,592,489)	4,517,741 (2,833,571)
Gross profit		2,221,808	1,684,170
Other income Administrative expenses Other expenses	6	2,880 (1,016,891) (7,422)	6,637 (865,656) (6,686)
Operating profit		1,200,375	818,465
Finance income Finance expenses Net foreign exchange transactions loss		24,107 (237,320) (55,095)	205,929 (239,810) (1,276)
Net finance expenses	8	(268,308)	(35,157)
Profit before taxation Taxation	9	932,067 54,660	783,308 (15,132)
Profit for the period		986,727	768,176
Total comprehensive income for the period		986,727	768,176
Profit for the period attributable to: Owners of the Company Non-controlling interests		896,869 89,858 986,727	687,305 80,871 768,176
		980,727	700,170
Total comprehensive income for the period attributable to:			
Owners of the Company Non-controlling interests		896,869 89,858	687,305 80,871
		986,727	768,176
Basic and fully diluted earnings per share (RUB)	10	11.98	9.18
man and run, under cut mings per smare (ROD)	10	11.70	7.10

The notes on pages 8 to 18 are an integral part of these condensed consolidated interim financial statements.

### CONDENSED CONSOLIDATED INTERIM STATEMENT OF FINANCIAL POSITION

### As at 30 June 2016 / 31 December 2015

	Note	30 June 2016 RUB'000	31 December 2015 RUB'000
ASSETS			
Property, plant and equipment	12	12,708,863	12,364,449
Intangible assets		2,467,695	2,144,818
Trade, other receivables and deferred expenses	14	127,584	184,344
Investments		2,000	2,403
Deferred tax assets		171,120	99,282
Total non-current assets		15,477,262	14,795,296
Inventories		366,252	327,365
Trade, other receivables and deferred expenses	14	328,396	257,889
Non-current assets held for sale		61,033	45,778
Current income tax asset		12,560	7,170
Cash and cash equivalents	15	1,275,067	1,774,312
Total current assets		2,043,308	2,412,514
Total assets		17,520,570	17,207,810
EQUITY AND LIABILITIES			
Share capital	16	180,585	180,585
Reserves		11,316,211	10,906,097
Total equity attributable to owners of the Company	-	11,496,796	11,086,682
Non-controlling interests		398,489	422,732
Total equity		11,895,285	11,509,414
Liabilities			
Loans and borrowings	17	1,982,699	2,292,567
Obligations under finance leases		6,744	7,359
Trade and other payables	18	227,973	243,045
Deferred tax liabilities		114,565	107,337
Deferred income	19	112,234	106,295
Total non-current liabilities	_	2,444,215	2,756,603
Loans and borrowings	17	1,128,550	1,161,339
Obligations under finance leases		1,213	1,196
Trade and other payables	18	1,086,370	873,443
Deferred income	19	942,193	885,622
Current income tax liability	_	22,744	20,193
Total current liabilities	_	3,181,070	2,941,793
Total liabilities	-	5,625,285	5,698,396
Total equity and liabilities		17,520,570	17,207,810
On 2 September 2016 the Board of Directors of MD	Madical (	From Investments 1	010 00000001 0001

On 2 September 2016 the Board of Directors of MD Medical Group Investments Plc approved and authorized these condensed consolidated interim financial statements for issue.

Vladimir Mekler

Director

Mark Kurtser

Managing Director

Vitaly Ustimenko

Director

The notes on pages 8 to 18 are an integral part of these condensed consolidated interim financial statements.

## CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY

For the period from 1 January 2016 to 30 June 2016

			Attrib	utable to the	Attributable to the owners of the Company	Company			
	Note	Share capital RUB'000	Share premium RUB'000	Treasury shares RUB'000	Other reserves RUB'000	Retained earnings RUB'000	Total RUB'000	Non- controlling interests RUB'000	Total equity RUB'000
Balance at 1 January 2016		180,585	5,243,319	(43,751)	(655,352)	6,361,881	11,086,682	422,732	11,509,414
Comprehensive income Profit for the period		1				896,869	896,869	89,858	986,727
Contributions by and distributions to owners Equity-settled share-based payment Dividends paid	Ξ	1 1	1 2	13,577	1 1	(500,332)	13,577 (500,332)	(114,101)	13,577 (614,433)
Balance at 30 June 2016		180,585	5,243,319	(30,174)	(655,352)	6,758,418	11,496,796	398,489	11,895,285

Share premium is not available for distribution.

# CONDENSED CONSOLIDATED INTERIM STATEMENT OF CHANGES IN EQUITY (continued)

For the period from 1 January 2015 to 30 June 2015

		Attr	ibutable to own	Attributable to owners of the Company	pany		Non-	
	Share capital Note RUB'000	Share premium RUB'000	Treasury shares RUB'000	Other reserves RUB'000	Retained earnings RUB'000	Total RUB'000	controlling interests RUB'000	Total equity RUB'000
Balance at 1 January 2015	180,585	5,243,319	(73,086)	(655,352)	5,058,812	9,754,278	382,316	10,136,594
Comprehensive income Profit for the period	X	1	1	1	687,305	687,305	80,871	768,176
Contributions by and distributions to owners Dividends paid	п	Ī			(300,329)	(300,329)	(60,439)	(360,768)
Changes in ownership interests Acquisition of subsidiaries with non-controlling interest	r	i	1		1	-	7,973	7,973
change in ownership in subsidiary	1	ī	1	1	(132)	(132)	132	
Balance at 30 June 2015	180,585	5,243,319	(73,086)	(655,352)	5,445,656	10,141,122	410,853	10,551,975

Share premium is not available for distribution.

### CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS

### For the period from 1 January to 30 June

	Note	2016 RUB'000	2015 RUB'000
Cash flows from operating activities			
Profit for the period		986,727	768,176
Adjustments for:		,	, , , , , ,
Depreciation of property, plant and equipment	5, 6	410,499	387,849
Equity-settled share-based payment transaction		13,577	-
(Gain) / loss from the sale of property, plant and			
equipment		(509)	399
Amortisation of intangible assets	6	46,436	46,280
Finance income	8	(24,107)	(205,929)
Finance expense	8	237,320	239,810
Net foreign exchange transactions loss	8	55,095	1,276
Taxation		(54,660)	15,132
Cash flows from operations before working capital			
changes		1,670,378	1,252,993
Decrease/(increase) in inventories		5,599	(15,527)
Increase in trade and other receivables		(37,553)	(3,202)
Increase in trade and other payables		106,107	67,530
Increase/(decrease) in deferred income		50,561	(2,920)
Cash flows from operations		1,795,092	1,298,874
Tax paid		(7,203)	(6,890)
Net cash flows from operating activities	_	1,787,889	1,291,984
Cash flows from investing activities Payment for acquisition/construction of property, plant			
and equipment		(526,753)	(339,396)
Proceeds from disposal of property, plant and			
equipment		-	37
Payment for acquisition of intangible assets		(7,778)	(3,350)
Acquisition of subsidiaries, net cash outflow on			
acquisition		(474,873)	(992)
Interest received		21,096	23,379
Net cash flows used in investing activities		(988,308)	(320, 322)

The notes on pages 8 to 18 are an integral part of these condensed consolidated interim financial statements.

### CONDENSED CONSOLIDATED INTERIM STATEMENT OF CASH FLOWS

### For the period from 1 January to 30 June

	Note	2016 RUB'000	2015 RUB'000
Cash flows from financing activities			
Proceeds from loans and borrowings		236,627	539
Repayment of loans and borrowings		(613,679)	(491,290)
Repayment of obligations under finance leases		(738)	(127)
Finance expenses paid		(217,365)	(240,046)
(Repayment of) / proceeds from reimbursed VAT	18	(50,445)	466,374
Payments on settlement of derivative financial			
instruments		(10,052)	=
Dividends paid to the owners of the Company		(500,332)	-
Dividends paid to non-controlling interests		(88,094)	(57,991)
Net cash flows used in financing activities	_	(1,244,078)	(322,541)
Net (decrease) / increase in cash and cash			
equivalents		(444,497)	649,121
Cash and cash equivalents at the beginning of the			
period	15	1,774,312	890,551
Effect of exchange rate changes on cash and cash			
equivalents		(54,748)	(8,340)
Cash and cash equivalents at the end of the	_		
period	15	1,275,067	1,531,332

### NOTES TO THE CONDENSED CONSOLIDATED INTERIM STATEMENTS

For the period from 1 January 2016 to 30 June 2016

### 1. INCORPORATION AND PRINCIPAL ACTIVITIES

MD Medical Group Investments Plc (the "Company") was incorporated in Cyprus on 5 August 2010 as a private limited liability company under the provisions of the Cyprus Companies Law, Cap. 113. In August 2012, following a special resolution passed by the shareholder, the Company was converted into a public limited liability company in accordance with the provisions of the Cyprus Companies Law, Cap. 113. Its registered office is situated at Dimitriou Karatasou 15, Anastasio Building, 6th floor, office 601, Strovolos, 2024, Nicosia, Cyprus.

The condensed consolidated interim financial statements for the period ended 30 June 2016 consist of the condensed consolidated interim statement of financial position as at the aforementioned date and the related condensed consolidated interim statements of comprehensive income, changes in equity and cash flows and a summary of significant accounting policies and other explanatory notes of the Company and its subsidiaries (which together are referred to as "the Group") for the reporting period.

The principal activity of the Company is that of an investment holding company and, for that purpose, to acquire and hold controlling and other interests in the share or loan capital of any company or companies of any nature, but primarily in the healthcare industry. Please refer to note 4 for more detailed information about the services provided by the Group's medical centres.

The details of the directly and indirectly owned subsidiaries are as follows:

<u>Name</u>	Country of incorporation	Activities	Notes	30 June 2016 Effective Holding	31 December 2015 Effective Holding %
CJSC MD PROJECT 2000	Russian Federation	Medical services		95	95
LLC Khaven	Russian Federation	Medical services		100	100
LLC Velum	Russian Federation	Medical services		54	54
LLC Capital Group	Russian Federation	Renting of property, retail		80	80
LLC FimedLab	Russian Federation	Medical services		60	60
LLC Clinic Mother and Child	Russian Federation	Holding of trademarks	1	100	100
LLC Clinica Zdorovia	Russian Federation	Medical services		60	60
LLC Ivamed	Russian Federation	Medical services		100	100
LLC Dilamed	Russian Federation	Medical services		100	100
CJSC Listom	Russian Federation	Service company		100	100
LLC Ustic-ECO	Russian Federation	Medical services		70	70
LLC Mother and Child Perm	Russian Federation	Medical services		80	80
LLC Mother and Child Ufa	Russian Federation	Medical services	2	80	80
LLC Mother and Child					
Saint-Petersburg	Russian Federation	Medical services	2	60	60
LLC MD PROJECT 2010	Russian Federation	Medical services		100	100
LLC Mother and Child					
Ugo-Zapad	Russian Federation	Medical services	2	60	60
LLC MD Service	Russian Federation	Pharmaceutics retail	4	95	95
LLC Mother and Child					
Nizhny Novgorod	Russian Federation	Medical services		100	100
LLC Mother and Child					
Yekaterinburg	Russian Federation	Medical services		100	100
LLC TechMedCom	Russian Federation	Service company	5	-	-
LLC Service Hospital					
Company	Russian Federation	Service company	5	-	-
Vitanostra Ltd	Cyprus	Holding of investments		100	100
LLC NPC MIR	Russian Federation	Holding of investments	6	100	100

### NOTES TO THE CONDENSED CONSOLIDATED INTERIM STATEMENTS

### For the period from 1 January 2016 to 30 June 2016

### 1. INCORPORATION AND PRINCIPAL ACTIVITIES (continued)

				30 June	31 December
				2016	2015
				Effective	Effective
	Country of			Holding	Holding
Name	incorporation	Activities	Notes	<u>%</u>	<u>%</u>
LLC MK IDK	Russian Federation	Medical services	6	100	100
LLC Apteka IDK	Russian Federation	Pharmaceutics retail	6	100	100
LLC CSR	Russian Federation	Medical services	6	100	100
LLC Centre of Reproductive					
Medicine	Russian Federation	Medical services		85	85
LLC MD Assistance	Russian Federation	Assistance services		100	100
LLC Mother and Child					
Yaroslavl	Russian Federation	Medical services		80	80
LLC MD Management	Russian Federation	Management company		100	100
LLC Mother and Child Ryazan	Russian Federation	Medical services		100	100
Shelly Management ltd	BVI	Holding of investments	6	100	100
Ivicend Holding Ltd	Cyprus	Holding of investments		100	100
CJSC MC Avicenna	Russian Federation	Medical services	7	100	100
LLC H&C Medical Group	Russian Federation	Medical services	7	100	100
LLC Elleprof	Russian Federation	Service company	5	-	
LLC Medtechnoservice	Russian Federation	Service company	5	-	-1
LLC Medica 2	Russian Federation	Medical services	3	100	100
LLC Mother and Child Siberia	Russian Federation	Medical services	8	100	
LLC Krasnoyarskii center of	Russian Federation	Medical services	8	100	-
Reproductive Medicine					
LLC Novosibirskii center of	Russian Federation	Medical services	8	100	-
Reproductive Medicine					
LLC Omskii center of	Russian Federation	Medical services	8	100	-
Reproductive Medicine					
LLC Barnaulskii center of	Russian Federation	Medical services	8	100	
Reproductive Medicine					
LLC Kostroma	Russian Federation	Medical services	9	100	-
LLC Siberia service company	Russian Federation	Service company	9	100	C1 2 1
		1			

### Notes:

- 1. 1% of the charter capital of this entity is directly owned by the Company and 99% of the charter capital of this entity is indirectly owned through LLC Khaven.
- 2. These entities are indirectly owned through LLC Khaven.
- 3. This entity was acquired in December 2015
- 4. 95% of the charter capital of the entity is directly owned by the Company, 3% of the charter capital, previously owned by LLC Clinica Zdorovia was sold in March 2015.
- 5. These entities, although not legally owned by the Group, are controlled by the Group since most of their activities are carried out on behalf of the Group.
- 6. These entities are indirectly owned through Vitanostra Ltd.
- 7. These entities are indirectly owned through Ivicend Holding Ltd.
- 8. These entities were acquired in January 2016 and are indirectly owned through Ivicend Holding Ltd.
- 9. These entities were incorporated in the six-month period ended 30 June 2016.

### NOTES TO THE CONDENSED CONSOLIDATED INTERIM STATEMENTS

For the period from 1 January 2016 to 30 June 2016

### 1. INCORPORATION AND PRINCIPAL ACTIVITIES (continued)

As at 30 June 2016, 67.9% of the Company's share capital is owned by MD Medical Holding Limited, a company beneficially owned by Dr. Mark Kurtser. The 31.8% of the Company's share capital is owned by Guarantee Nominee Limited, who holds the shares on behalf of the GDR holders. The remaining 0.3% of the Company's share capital is owned by the Company.

### 2. BASIS OF PREPARATION

### (a) Statement of compliance

These condensed consolidated interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting, and should be read in conjunction with the Group's last annual consolidated financial statements. They do not include all the information required for a complete set of IFRS financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual consolidated financial statements as at 31 December 2015 and for the year then ended.

### (b) Basis of measurement

The condensed consolidated interim financial statements have been prepared under the historical cost convention.

### (c) Use of estimates and judgements

Preparing these condensed consolidated interim financial statements requires management to exercise their judgement to make estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense.

The estimates and underlying assumptions are based on historical experience and various other factors that are deemed to be reasonable based on knowledge available at that time. Actual results may differ from these estimates.

The significant judgements made by the management in applying the Group accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements for the year ended 31 December 2015.

### (d) Functional and presentation currency

All of the operational Group entities are located in the Russian Federation. The Company and its major operating subsidiaries have RUB as their functional currency.

The condensed consolidated interim financial statements of the Company are presented in RUB, rounded to the nearest thousand.

### 3. SIGNIFICANT ACCOUNTING POLICIES

The accounting policies applied in these condensed consolidated interim financial statements are consistent with those followed in the Group's consolidated financial statements as at 31 December 2015 and for the year then ended. Several new standards and amendments apply for the first time in 2016. However, they do not significantly impact these condensed consolidated interim financial statements of the Group.

### NOTES TO THE CONDENSED CONSOLIDATED INTERIM STATEMENTS

### For the period from 1 January 2016 to 30 June 2016

### 4. REVENUE

	30 June 2016 RUB'000	30 June 2015 RUB'000
IVF	1,174,646	710,686
Deliveries	1,085,649	848,885
Obstetrics and Gynaecology out-patient treatments	836,704	710,328
Paediatrics out-patient treatments	567,641	499,297
Obstetrics and Gynaecology in-patient treatments	463,839	383,302
Paediatrics in-patient treatments	195,088	142,973
Other out-patient medical services	499,656	390,948
Other in-patient medical services	249,704	212,875
Other medical services	516,107	431,860
Sales of goods	161,272	128,936
Other income	63,991	57,651
	5,814,297	4,517,741

The significant increase of revenue was mostly due to the increase of utilisation of Lapino, Ufa hospitals and results of entities acquired in December 2015 and January 2016.

### 5. COST OF SALES

	30 June 2016 RUB'000	30 June 2015 RUB'000
Payroll and related social taxes	1,995,310	1,623,911
Materials and supplies used	935,676	621,011
Depreciation	352,681	336,631
Medical services	111,943	83,077
Energy and utilities	64,387	60,899
Property tax	48,318	50,277
Repair and maintenance	43,858	29,113
Other expenses	40,316	28,652
	3,592,489	2,833,571

### 6. ADMINISTRATIVE EXPENSES

	30 June 2016 RUB'000	30 June 2015 RUB'000
Payroll and related social taxes	561,606	488,131
Utilities and materials	103,248	86,194
Other professional services	83,948	79,626
Advertising	78,375	54,630
Depreciation	57,818	51,218
Amortisation	46,436	46,280
Communication costs	14,219	11,694
Independent auditors' remuneration	6,917	6,284
Other expenses	64,324	41,599
	1,016,891	865,656

The consulting services provided by the audit company was nil for both six months periods ended 30 June 2016 and 30 June 2015.

### NOTES TO THE CONDENSED CONSOLIDATED INTERIM STATEMENTS

### For the period from 1 January 2016 to 30 June 2016

### 7. STAFF COSTS

		30 June 2016 RUB'000	30 June 2015 RUB'000
	Wages and salaries Social insurance contributions and other taxes	1,999,280 557,636	1,647,016 465,026
	Total staff costs	2,556,916	2,112,042
8.	NET FINANCE EXPENSES		
		30 June 2016 RUB'000	30 June 2015 RUB'000
	Finance income		
	Bank interest received	20,998	23,273
	Interest from loans to third parties	98	106
	Bad debts recovered	3,011	4,416
	Income on discounting	-	178,134
		24,107	205,929
	Finance expenses		
	Interest expense		
	Interest on bank loans	(145,243)	(197,960)
	Interest on loans from third parties	(1,627)	(276)
	Finance leases interest	(140)	(23)
	Other finance expense		
	Bank charges	(56,076)	(39,577)
	Unwinding of discount on other payables to tax authorities (note 18)	(32,799)	-
	Impairment of trade and other receivables	(1,435)	(1,974)
		(237,320)	(239,810)
	Net foreign exchange transaction loss	(55,095)	(1,276)
	Net finance expense	(268,308)	(35,157)

### 9. TAXATION

The Group recognized tax benefit of RUB54,660 thousand in the reporting period mostly due to the increase in the deferred tax assets for MD Medical Group Investments Plc and LLC MD Project 2010, whose profits are taxable at 20% and tax losses were incurred in 2016.

Income tax was recognized at the annual effective tax rate of minus 6% expected for 2016.

### NOTES TO THE CONDENSED CONSOLIDATED INTERIM STATEMENTS

### For the period from 1 January 2016 to 30 June 2016

### 10. EARNINGS PER SHARE

	30 June 2016	30 June 2015
Basic and fully diluted earnings attributable to the owners of the Company		
(RUB'000)	896,869	687,305
Weighted average number of ordinary shares in issue during the period	74,895,010	74,895,010
Basic and fully diluted earnings per share (RUB)	11.98	9.18

### 11. DIVIDENDS

On 18 March 2016 the Board of Directors declared a final dividend for the year 2015 amounting to RUB500,332 thousand (USD7,298 thousand), which corresponds to RUB6.66 (USD0.1) per share. The dividend distribution was approved by the Annual General Meeting of the shareholders on 15 April 2016. The dividend was paid on 20 May 2016.

### 12. PROPERTY, PLANT AND EQUIPMENT

Additions to property, plant and equipment amounted to RUB771,490 thousand incurred during the six months period ended 30 June 2016 and mostly related to the continuing construction of a hospital in the Russian city Novosibirsk and the acquisition of new entities in January 2016 (note 13).

The total net book value of property, plant and equipment which is held as collateral for the loans and borrowings is RUB5,476,163 thousand as at 30 June 2016 (31 December 2015: RUB5,560,245 thousand)

### 13. ACQUISITION OF SUBSIDIARIES

In the end of January 2016 the Company acquired 100% shares in five entities from a third party. All these entities are registered under Russian laws and located in Krasnoyarsk, Omsk, Novosibirsk and Barnaul. The acquisition was for a cash consideration of RUB485,000 thousand. The acquisition is consistent with MDMG's strategy for regional expansion and the development of a high quality network of out-patient clinics focusing on IVF, obstetrics, gynecology and pediatrics.

Goodwill arising on consolidation is as follows:

	RUB'000
Consideration transferred - cash	485,000
Less: Fair value of the net assets acquired	(124,847)
Goodwill arising on consolidation	360,153

The consideration paid for the combination effectively included amounts in relation to the benefits of expected synergies, revenue growth, future market development, personnel qualification and local reputation. These benefits are not recognized separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets.

### NOTES TO THE CONDENSED CONSOLIDATED INTERIM STATEMENTS

### For the period from 1 January 2016 to 30 June 2016

### 13. ACQUISITION OF SUBSIDIARIES (continued)

The fair values of assets and liabilities acquired were as follows:

	RUB'000
Intangible assets	1,381
Property, plant and equipment	131,253
Inventories	44,486
Deferred tax assets	1,799
Trade, other receivables and deferred expenses	19,479
Current tax assets	2,716
Cash and cash equivalents	14,200
Current tax liabilities	(661)
Loans and borrowings	(32,923)
Deferred income	(11,949)
Trade and other payables	(44,934)
Net assets	124,847

The fair value of property, plant and equipment recognized as a result of the business combinations was measured using the following valuation techniques:

- the average between market and income approach for the buildings. Fair values based on the market approach were calculated by using prices generated by market transactions involving comparable property, plant and equipment. Fair values based on income approach were calculated by discounting estimated future cash flows at market rental rates.
- the average amount of the cost approach and the market approach for equipment. Fair values based on
  the market approach were calculated by using prices generated by market transactions involving identical
  or comparable equipment. Fair values based on cost approach were calculated by using current
  replacement cost. Current replacement cost reflects an amount that is required to replace the service
  capacity of equipment.

The net cash outflow on acquisition of subsidiaries was as follows:

	RUB'000
Consideration paid in cash	485,000
Cash and cash equivalents acquired	(14,200)
	470,800

### Contribution to the Group results

The amount of additional revenue that would have been contributed to the Group had the acquisition occurred at the beginning of the reporting period is approximately RUB33,643 thousand. The disclosure of the amount of profit that would have been contributed to the Group is impracticable to be estimated accurately since the acquired company has not reported financial information under IFRS.

### NOTES TO THE CONDENSED CONSOLIDATED INTERIM STATEMENTS

For the period from 1 January 2016 to 30 June 2016

### 14. TRADE, OTHER RECEIVABLES AND DEFERRED EXPENSES

		30 June 2016 RUB'000		ember 2015 JB'000
Trade receivables		198,625	5	152,230
CAPEX prepayments		127,584		184,344
Advances paid to suppliers		84,679	)	72,766
Deferred expenses		18,793		13,715
Other receivables	-	26,299	<del></del>	19,178
	-	455,980	)	442,233
Non-current portion		127,584		184,344
Current portion		328,390	<u> </u>	257,889
	-	455,980	)	442,233
15. CASH AND CASH EQUIVALENTS				
Cash balances are analysed as follows:				
,		30 June 2016 RUB'000		ember 2015 JB'000
Cash at bank and in hand Bank deposits with maturity less than 3 months		325,444 949,623		402,335 1,371,977
		1,275,067		1,774,312
		30 June 2016	31 Dece	ember 2015
Currency:		RUB'000	RU	JB'000
Russian Ruble		617,40	0	639,499
Euro		5,51		2,366
United States Dollar	_	652,15	3	1,132,447
	_	1,275,06	7	1,774,312
16. SHARE CAPITAL				
	Number of	Nominal	Share	Share
	shares	value	capital	capital
	Situ Vo	US\$	RUB'000	US\$'000
Authorised share capital	125,250,00	0.08		10,020
Issued and fully paid ordinary shares	75,125,01	0.08	180,585	6,010

### NOTES TO THE CONDENSED CONSOLIDATED INTERIM STATEMENTS

### For the period from 1 January 2016 to 30 June 2016

### 17. LOANS AND BORROWINGS

	30 June 2016 RUB'000	31 December 2015 RUB'000
Long term liabilities		
Bank loans	1,982,699	2,292,567
Short term liabilities		
Bank loans	1,092,098	1,092,516
Other loans	36,452	68,823
	1,128,550	1,161,339
Maturity of loans and borrowings:		
Within one year	1,128,550	1,161,339
Between one and five years	1,960,225	2,217,710
More than 5 years	22,474	74,857
	3,111,249	3,453,906

The total net book value of property, plant and equipment which is held as collateral for the bank loans is disclosed in note 12. As additional collateral the Company has pledged the shares of CJSC MD Project 2000 and LLC Khaven.

As at 30 June 2016, the terms and debt repayment schedule of loans is as follows:

	Currency	Nominal interest rate	Year of maturity	30 June	2016	31 Decem	ber 2015
				Face value RUB'000	Carrying amount RUB'000	Face value RUB'000	Carrying amount RUB'000
Secured bank loan	RUB	9%	2018	1,249,504	1,249,504	1,588,634	1,588,634
Secured bank loan	RUB	10.8%	2019	658,824	658,824	753,165	753,165
Secured bank loan	RUB	10.8%	2019	441,175	441,175	500,845	500,845
Secured bank loan	RUB	9%	2018	236,446	236,446	284,446	284,446
Unsecured bank loan	RUB	11.4%	2022	450,613	450,613	213,875	213,875
Unsecured bank loan	RUB	14.2%	2019	38,235	38,235	44,118	44,118
Unsecured other loan	RUB	8.5%-14.5%	2016	35,084	35,084	-	-
Unsecured other loan	RUB	16%	2016	1,368	1,368	68,823	68,823
				3,111,249	3,111,249	3,453,906	3,453,906

### NOTES TO THE CONDENSED CONSOLIDATED INTERIM STATEMENTS

For the period from 1 January 2016 to 30 June 2016

### 18. TRADE AND OTHER PAYABLES

	30 June 2016 RUB'000	31 December 2015 RUB'000
Accruals	331,007	246,207
Trade payables	253,124	214,831
Other payables to tax authorities (*)	270,593	288,239
Payables to employees	200,771	182,443
Taxes payable	154,314	138,617
CAPEX payables	58,041	14,695
Dividend payable	26,007	
Other payables	20,486	31,456
	1,314,343	1,116,488
Non-current portion	227,973	243,045
Current portion	1,086,370	873,443
	1,314,343	1,116,488

<sup>(\*)</sup> Other payables to tax authorities include input VAT reimbursed in June 2015. Decrease of the payable resulted from a partial repayment of the liability in the amount of RUB50,445 thousand and unwinding of the discount of RUB32,799 thousand (note 8).

### 19. DEFERRED INCOME

Deferred income that relates to long term client advances represents money received from patients on stem cells storage contracts lasting from 1 to 20 years.

Deferred income that relates to short term client advances represents money received from patients on stem cells storage contracts, childbirth management contracts lasting from 1 to 9 months, and children care contracts valid for a specified period of time.

### 20. RELATED PARTY TRANSACTIONS

### 20.1 Key management personnel

The remuneration of the members of the key management personnel and non-executive directors for the six months ended 30 June 2016 was RUB19,181 thousand (for six months ended 30 June 2015: RUB12,679 thousand).

The company received legal services from the key management personnel for the six months ended 30 June 2016 amounted to RUB730 thousand (for the six months ended 30 June 2015; RUB138 thousand).

### 20.2 Directors' interests

The direct and indirect interests of the members of the Board in titles of the Company as at 30 June 2016 and as at the date of signing these condensed consolidated interim financial statements are as follows:

Name	Type of interest	Effective interest %
Mark Kurtser	Indirect ownership of shares	67.90
Kirill Dmitriev	Indirect interest in shares	5.55
Simon Rowlands	Direct ownership of shares	0.33

### NOTES TO THE CONDENSED CONSOLIDATED INTERIM STATEMENTS

For the period from 1 January 2016 to 30 June 2016

### 20. RELATED PARTY TRANSACTIONS (continued)

Indirect interest in shares by Kirill Dmitriev arises through his capacity as key management personnel of indirect shareholder.

The calculation of effective interest is based on the total amount of issued and fully paid shares, including treasury shares acquired by the Company.

### 21. CAPITAL COMMITMENTS

Capital expenditure contracted for at the reporting date but not yet incurred as at 30 June 2016 amounted to RUB672,832 thousand (as at 31 December 2015: RUB780,907 thousand.)

### 22. EVENTS AFTER THE REPORTING PERIOD

In August 2016 the Company has signed a construction contract with a general contractor relating to the construction of a new multi-disciplinary hospital in Samara. The total amount of the project will be approximately RUB3.5 billion. A part of this amount will be financed by a new loan.

On 18 July 2016 the Company announced signing a Memorandum of Understanding with the Tyumen Regional Government to evaluate the potential to build a new multi-disciplinary hospital in the region.